Case Studies

In this case study, Dr. Arpeet Shah, board-certified urologist at Associated Urological Specialists, discusses a case involving a patient with elevated PSA and PI-RADS 3. Dr. Shah utilized IsoPSA to assess risk and guide his decision on whether to biopsy. The IsoPSA result provided Dr. Shah with the confidence to forgo biopsy and continue patient monitoring at this time.

Dr. Arpeet Shah, board-certified urologist at Associated Urological Specialists, has found IsoPSA to be a clinically useful tool for patient monitoring. In this case, he ordered an IsoPSA test for a patient with a PI-RADS 3 lesion and elevated PSA. The IsoPSA result was normal, and biopsy confirmed Gleason 6 prostate cancer. Dr. Shah chose to monitor the patient using IsoPSA. Two years later, the patient’s Total PSA remained stable, but his IsoPSA Index had become abnormal. Based on that result, Dr. Shah performed a repeat biopsy, which revealed progression to Gleason 7 prostate cancer.

A 63-year-old male with Gleason 6 (GG1) prostate cancer currently on Active Surveillance, has family history of prostate cancer and a PSA of 7.2 ng/mL.

This case study involves a 62-year-old African American male referred by his PCP with a PSA of 6.2 ng/mL and DRE with no abnormal findings except prostate enlargement.

A 67-year-old male presents with a PSA of 4.5ng/mL, no family history, and PI-RADS 3 on MRI.

This case study involves a 58-year-old male being treated for BPH whose PSA levels at 6.1 ng/mL and had a normal DRE other than enlargement (50gm prostate).

A 64-year-old male referred for PSA of 4.8 ng/mL, mpMRI read as “no findings suspicious for cancer” and prostate volume of 36cc.